News Conference News ESC 2025 Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF Michael O'Riordan August 29, 2025
News Conference News ESC 2024 SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients Michael O'Riordan September 02, 2024
News ESC 2023 Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST Michael O'Riordan August 27, 2023
News Conference News ESC 2022 COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19 Todd Neale September 01, 2022
News Conference News ESC 2022 Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration Michael O'Riordan August 29, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Conference News ESC 2021 New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy Michael O'Riordan September 03, 2021
News Conference News ESC 2021 No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER Michael O'Riordan September 02, 2021
News Conference News ESC 2020 Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF Michael O'Riordan August 31, 2020
News Conference News ESC 2020 Trimetazidine Safe but Not Protective Long-term After PCI Caitlin E. Cox August 30, 2020
News Conference News ESC 2019 CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients Shelley Wood September 03, 2019
News Conference News ESC 2018 GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI Michael O'Riordan August 27, 2018
News Conference News ESC 2018 Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE Shelley Wood August 26, 2018
News Conference News ESC 2017 CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events Michael O'Riordan August 27, 2017
News Conference News ESC 2013 Length of DAPT, Reasons for Discontinuation Have Disparate Effects Yael L. Maxwell September 01, 2013